QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

Inclusion Criteria: * Age between 18 and 75 years. * Histologically or clinically confirmed initially resectable Stage III colon cancer according to the AJCC 8th edition. * ECOG performance status of 0 or 1. * pMMR/MSS status confirmed by a local testing center. * No planned neoadjuvant radiotherapy. * Participants must voluntarily participate in the study, sign an informed consent form, and demonstrate good compliance. * Adequate organ function. Exclusion Criteria: * Stage IV colon cancer. * Prior treatment with immune checkpoint inhibitors targeting CTLA-4, PD-1, or PD-L1. * Current participation in another clinical trial and receiving investigational drugs. * History of or contraindication to severe allergic reactions to immunotherapy. * Pregnancy or lactation. * Active infection requiring treatment. * Use of immunosuppressive medications. * Active cardiovascular disease, including stroke or myocardial infarction within 6 months before enrollment, unstable angina, congestive heart failure, or severe uncontrolled arrhythmia requiring medication that may preclude surgery. * Patients with acute conditions such as obstruction, hemorrhage, or perforation that require immediate surgery. * Any other condition deemed by the investigator to render the participant unsuitable for the clinical study.